Jae Park on Clinical Trials for CAR T-Cell Activation Therapy

March 29, 2016
Jae Park, MD

Jae Park, MD, hematologist-oncologist, Memorial Sloan Kettering Cancer Center, talks about CAR T-cell activation therapy, which is currently in clinical trials for patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.

Jae Park, MD, hematologist-oncologist, Memorial Sloan Kettering Cancer Center, talks about CAR T-cell activation therapy, which is currently in clinical trials for patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.

Park says the trials show an 80% success rate for patients with ALL using the CAR T activation, and despite his hopes that it will eventually become a frontline therapy, not all patients are currently eligible for the trial.

Patients with ALL, CLL, or non-Hodgkin lymphoma who want to participate must have received at least one other therapy, such as a bone marrow transplant or chemotherapy, that has not worked.